Skip to content
Clinical Trials – home

Rare diseases

Investigational molecules

Locations

Our offerNewsroom

GermanyBack to Germany

Clinical trials in Leipzig – page 10

767 clinical trials in Leipzig, Germany across 5 research sites. Every trial is listed in the EU Clinical Trials Register and updated daily.

GermanyOur site in GermanyKlinischeStudien.de(opens in a new tab)
Leipzig at a glance
767
clinical trials
  • Research sites5
Type of trial
Recruitment status
Quick filters

767 trials in Leipzig

Open in trial search

Acute myeloid leukaemia

Recruiting

Study of ziftomenib with drug combinations for adults with newly diagnosed acute myeloid leukemia with NPM1 or KMT2A genetic changes

Registered drug
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Azacitidine
  • Sponsor:Kura Oncology Inc.

Metabolic dysfunction-associated liver disease

Recruiting

N1T-MC-MALO: A Master Protocol for a Randomized, Controlled, Clinical Trial of Multiple Pharmacologic Agents in Adult Participants With Metabolic Dysfunction-Associated Steatotic Liver Disease Who Are at Increased Risk of Developing Major Adverse Liver Outcomes (SYNERGY-Outcomes); N1T-MC-TZ01 Tirzepatide in participants with high-risk MASLD; N1T-MC-RT01 Retatrutide in participants with high-risk MASLD

Investigational
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:LY3437943 sodium
  • Sponsor:Eli Lilly & Co.

Bronchopulmonary dysplasia

Recruiting

Evaluation of Retinol Palmitate Administration and Serum Levels in Preterm Infants with Bronchopulmonary Dysplasia: A Phase 2a Open-Label Study

InvestigationalNo placebo
Countries:GermanyGermany
  • Participants:0–17 years
  • Substances:Retinol Palmitate
  • Sponsor:Aspire Pharma Limited

Breast cancer metastatic

Recruiting

Phase 1b-2 Study of Elacestrant and Abemaciclib in Patients with Brain Metastases from ER-Positive, HER2-Negative Breast Cancer

Registered drugNo placebo
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Abemaciclib
  • Sponsor:Stemline Therapeutics Inc.

Acute kidney injury

Recruiting

A study testing how well AZD4144 works and how safe it is for adults with acute kidney injury caused by sepsis

Investigational
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Sponsor:AstraZeneca AB

Hodgkin's disease

Recruiting

A Study of Pembrolizumab and Radiotherapy for Patients with Early-Stage Favorable Classic Hodgkin Lymphoma

Registered drugNo placebo
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Pembrolizumab
  • Sponsor:University Of Cologne

Hormone receptor positive breast cancer

Recruiting

A Study of Camizestrant and Ribociclib for Patients with Hormone Receptor-Positive Breast Cancer

Registered drugNo placebo
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Camizestrant
  • Sponsor:Medica Scientia Innovation Research S.L.

Short-bowel syndrome

Recruiting

Study of glepaglutide compared to placebo for patients with short bowel syndrome with intestinal failure

Investigational
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Glepaglutide
  • Sponsor:Zealand Pharma A/S

Osteoarthritis

Recruiting

A Study of Orforglipron for Knee Pain Relief in Adults with Obesity or Overweight and Knee Osteoarthritis

Investigational
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Sponsor:Eli Lilly & Co.

Non-small cell lung cancer stage IIIA+2

Recruiting

Testing MK-2870 with pembrolizumab compared to pembrolizumab alone after surgery in patients with non-small cell lung cancer who did not respond fully to treatment

Registered drugNo placebo
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Carboplatin
  • Sponsor:Merck Sharp & Dohme LLC

Myasthenia gravis

Recruiting

Study of oral cladribine compared to placebo for patients with generalized myasthenia gravis

Registered drug
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Cladribine
  • Sponsor:Merck Healthcare KGaA

B-cell type acute leukaemia

Recruiting

Study of chemotherapy with blinatumomab and tyrosine kinase inhibitors in newly diagnosed children and young adults with Philadelphia chromosome positive B-cell acute lymphoblastic leukemia

Registered drugNo placebo
Countries:GermanyGermany
  • Participants:0–17 years · 18–64 years
  • Substances:Blinatumomab
  • Sponsor:Universita Degli Studi Di Milano Bicocca

Other cities in Germany

The busiest research cities in the country

All 518 cities in Germany

Clinical research in Leipzig

What the registry says about research in the country

01 Respiratory Diseases

Clinical trials focusing on respiratory infections and preventive vaccines, including studies for RSV and human metapneumovirus in elderly populations, as well as research on uncontrolled asthma treatments.

  • RSV Prevention Studies
  • Asthma Management
  • Respiratory Virus Vaccines

Novel therapeutic approaches are being evaluated to protect vulnerable populations against respiratory infections.

02 Oncology Research

Innovative studies targeting various cancer types, with emphasis on breast cancer, lung cancer, and gastric cancer treatments using targeted therapies and immunotherapy approaches.

  • Advanced Solid Tumors
  • HER2-Positive Cancers
  • Combination Therapies

Focus on personalized treatment approaches and novel drug combinations to improve patient outcomes.

03 Infectious Diseases

Research centered on preventing and treating various infections, including studies of meningococcal vaccines in different age groups and cytomegalovirus prevention strategies.

  • Vaccine Development
  • Pediatric Prevention
  • Immunization Studies

Comprehensive vaccine trials aimed at protecting diverse population groups against serious infections.

Back to GermanyAll countries
Clinical Trials Concierge

Prefer not to search? Our Concierge searches the trials for you.

Tell us about your condition – we search every trial in Europe and connect you with the right site.